Market news

HCW Biologics Inc. (NASDAQ:HCWB) has entered into an exclusive distribution agreement with Akron Biotech covering HCW11-006, its multi-cytokine fusion molecule designed for use as a reagent in CAR-T cell manufacturing.

Agreement includes pre-payment commitments for product sales and distribution of the second-generation multi-cytokine-based HCW11-006 for use as a reagent Akron is a leading supplier of critical ancillary materials and accessory molecules for clinical and commercial scale-up of cell, gene and regenerative therapy products HCW Biologics supplies research and cGMP-grade HCW11-006 and Akron markets and distributes the reagent to its established network of research institutions and commercial compan

Human studies show that the TGF-β trap and IL-15 fusion used alone promotes expansion of progenitor CD8+ T cells and NK cells Company has incorporated the TGF-β/IL-15 moiety into the constructs of its second-generation fusion immunotherapeutics constructed with novel TRBC drug development platform MIRAMAR, Fla., Aug. 25, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on developing novel

Detailed price information for Hcw Biologics Inc (HCWB-Q) from The Globe and Mail including charting and trades.

MIRAMAR, Fla., July 29, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to treat autoimmune diseases, cancer and senescence-associated dysplasia, today announced the pricing of its $1.6 million private placement offering (the “Offering”) with a group of investors, including officers, directors and an existing stockholder of the Company, (each, and “Invest

HCW Biologics (HCWB) said Wednesday it has priced an offering of 618,682 units to a group of investo

Company requested Type B pre-IND meeting with U.S. FDA to discuss development and regulatory strategy for its investigational tetravalent T-cell engager, HCW11-018b HCW11-018b has demonstrated potential for treating solid tumors that overexpress human tissue factor, including gynecologic and pancreatic cancers Company has developed a streamlined, robust manufacturing process designed to produce high-quality cGMP material at a lower cost than current methods MIRAMAR, Fla., July 23, 2026 (GLOBE NE